T cell receptor peptide therapy for autoimmune disease

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Synthetic peptides corresponding to germline T cell receptor (TCR) Vβ sequences shared by encephalitogenic T cells can prevent and treat experimental autoimmune encephalomyelitis in rats. The operative mechanism apparently involves boosting of anti-TCR immunity that develops during the course of experimental autoimmune encephalomyelitis (EAE), leading to the induction of autoregulatory T cells and antibodies. Striking parallels are present between patients with multiple sclerosis and animals with EAE in the T cell frequency and TCR V gene bias of BP reactive T cells, suggesting the involvement of an encephalitogenic process in multiple sclerosis. Preliminary trials with the appropriate human TCR peptides indicate that anti-TCR immunity can be boosted efficiently and safely, with concomitant loss of BP response, thus providing an effective strategy for selective regulation of autoimmunity in man.

Original languageEnglish (US)
Pages (from-to)83-92
Number of pages10
JournalJournal of Autoimmunity
Volume5
Issue numberSUPPL. A
DOIs
StatePublished - 1992

Fingerprint

T-Cell Antigen Receptor
Autoimmune Diseases
Autoimmune Experimental Encephalomyelitis
T-Lymphocytes
Peptides
Multiple Sclerosis
Immunity
T-Cell Receptor Genes
Therapeutics
Autoimmunity
Antibodies
Thomsen-Friedenreich antibodies

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

T cell receptor peptide therapy for autoimmune disease. / Vandenbark, Arthur; Chou, Yuan K.; Bourdette, Dennis; Whitham, Ruth; Hashim, George A.; Offner, Halina.

In: Journal of Autoimmunity, Vol. 5, No. SUPPL. A, 1992, p. 83-92.

Research output: Contribution to journalArticle

@article{1f6cdf8e23eb4ea7b7d2a05e32b9617e,
title = "T cell receptor peptide therapy for autoimmune disease",
abstract = "Synthetic peptides corresponding to germline T cell receptor (TCR) Vβ sequences shared by encephalitogenic T cells can prevent and treat experimental autoimmune encephalomyelitis in rats. The operative mechanism apparently involves boosting of anti-TCR immunity that develops during the course of experimental autoimmune encephalomyelitis (EAE), leading to the induction of autoregulatory T cells and antibodies. Striking parallels are present between patients with multiple sclerosis and animals with EAE in the T cell frequency and TCR V gene bias of BP reactive T cells, suggesting the involvement of an encephalitogenic process in multiple sclerosis. Preliminary trials with the appropriate human TCR peptides indicate that anti-TCR immunity can be boosted efficiently and safely, with concomitant loss of BP response, thus providing an effective strategy for selective regulation of autoimmunity in man.",
author = "Arthur Vandenbark and Chou, {Yuan K.} and Dennis Bourdette and Ruth Whitham and Hashim, {George A.} and Halina Offner",
year = "1992",
doi = "10.1016/0896-8411(92)90023-J",
language = "English (US)",
volume = "5",
pages = "83--92",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "SUPPL. A",

}

TY - JOUR

T1 - T cell receptor peptide therapy for autoimmune disease

AU - Vandenbark, Arthur

AU - Chou, Yuan K.

AU - Bourdette, Dennis

AU - Whitham, Ruth

AU - Hashim, George A.

AU - Offner, Halina

PY - 1992

Y1 - 1992

N2 - Synthetic peptides corresponding to germline T cell receptor (TCR) Vβ sequences shared by encephalitogenic T cells can prevent and treat experimental autoimmune encephalomyelitis in rats. The operative mechanism apparently involves boosting of anti-TCR immunity that develops during the course of experimental autoimmune encephalomyelitis (EAE), leading to the induction of autoregulatory T cells and antibodies. Striking parallels are present between patients with multiple sclerosis and animals with EAE in the T cell frequency and TCR V gene bias of BP reactive T cells, suggesting the involvement of an encephalitogenic process in multiple sclerosis. Preliminary trials with the appropriate human TCR peptides indicate that anti-TCR immunity can be boosted efficiently and safely, with concomitant loss of BP response, thus providing an effective strategy for selective regulation of autoimmunity in man.

AB - Synthetic peptides corresponding to germline T cell receptor (TCR) Vβ sequences shared by encephalitogenic T cells can prevent and treat experimental autoimmune encephalomyelitis in rats. The operative mechanism apparently involves boosting of anti-TCR immunity that develops during the course of experimental autoimmune encephalomyelitis (EAE), leading to the induction of autoregulatory T cells and antibodies. Striking parallels are present between patients with multiple sclerosis and animals with EAE in the T cell frequency and TCR V gene bias of BP reactive T cells, suggesting the involvement of an encephalitogenic process in multiple sclerosis. Preliminary trials with the appropriate human TCR peptides indicate that anti-TCR immunity can be boosted efficiently and safely, with concomitant loss of BP response, thus providing an effective strategy for selective regulation of autoimmunity in man.

UR - http://www.scopus.com/inward/record.url?scp=0026505191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026505191&partnerID=8YFLogxK

U2 - 10.1016/0896-8411(92)90023-J

DO - 10.1016/0896-8411(92)90023-J

M3 - Article

VL - 5

SP - 83

EP - 92

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - SUPPL. A

ER -